NeOnc Adds Banking Executive to Board as Brain Cancer Program Advances in Abu Dhabi
NeOnc Technologies appointed Ali Alabedin, a senior First Abu Dhabi Bank executive, to its board on October 9, 2026, replacing Dr. Steven L. Giannotta, who remains on its scientific advisory board. The company is developing NEO212 for difficult-to-treat brain cancers and has received investigational new drug authorization from Abu Dhabi's Department of Health, though this is not marketing approval and enrollment has not necessarily started. NeOnc also reported positive Phase 2a data for NEO100 and plans an FDA End-of-Phase 1 meeting for NEO212 on November 17, 2026.
NeOnc Technologies Holdings, traded as NTHI, named Ali Alabedin to its board on Oct. 9, 2026. He leads Islamic banking at First Abu Dhabi Bank and brings over 30 years in international finance, governance, and business leadership. He replaces Dr. Steven L. Giannotta, who left the board but stays on the scientific advisory panel.
The company is developing NEO212 for hard-to-treat brain cancers. Abu Dhabi's health department granted investigational new drug authorization, subject to ethics and pre-enrollment requirements; this is not marketing approval. NeOnc also reported NEO100 Phase 2a data: 48.9% six-month progression-free survival versus a 20% target, and median overall survival of 26.09 months. An FDA End-of-Phase 1 meeting for NEO212 is set for Nov. 17, 2026.
For patients with hard-to-treat brain cancers and their families, NeOnc's progress could eventually broaden trial access and treatment choices, though regulatory authorization alone does not guarantee benefit. Clinicians in the UAE may gain another research avenue if ethics clearance and enrollment proceed. The appointment of a senior banking figure may also strengthen the company's regional credibility, potentially affecting investors and Abu Dhabi's life-sciences sector. These are possibilities, not confirmed outcomes.